• Vanta launched a non-brokered private placement of up to 2,500,000 units at USD 1 each to raise up to USD 2.5 million.
• Each unit includes one common share plus one transferable warrant to buy one share at USD 1.25 for 24 months.
• Proceeds earmarked for U.S. peptide market entry, product commercialization, balance sheet payables, corporate awareness, working capital.
• Closing targeted on or about June 30, 2026, with the financing potentially completed in multiple tranches.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vanta Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202605292200ACCESSWRNAPR_____1172006) on May 30, 2026, and is solely responsible for the information contained therein.